enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
enVVeno Medical (NASDAQ:NVNO) regained compliance with Nasdaq Listing Rule 5550(a)(2) after its common stock maintained a closing bid of at least $1.00 for 10 consecutive business days, from January 20, 2026 through February 2, 2026.
Rhea-AI Summary
enVVeno Medical (NASDAQ:NVNO) regained compliance with Nasdaq Listing Rule 5550(a)(2) after its common stock maintained a closing bid of at least $1.00 for 10 consecutive business days, from January 20, 2026 through February 2, 2026. Nasdaq confirmed the matter is closed.
The company reported year-end cash and investments of approximately $28 million as of December 31, 2025 and said it has made meaningful progress on its 2026 strategic plans, with additional details expected in the coming weeks.
Positive
- Regained Nasdaq compliance after 10 consecutive business days ≥ $1.00 closing bid
- $28M cash and investments reported as of December 31, 2025
Details
News Market Reaction – NVNO
On Feb 4, the day this news came out, NVNO closed 8.21% below the previous close.
Data tracked by StockTitan Argus for the Feb 4 session.
Key Figures
- Minimum bid price
- $1.00 per share
- Nasdaq Listing Rule 5550(a)(2) requirement
- Compliance period
- 10 business days
- Consecutive days with closing bid at or above $1.00
- Compliance window dates
- Jan 20, 2026 – Feb 2, 2026
- Period Nasdaq cited for minimum bid compliance
- Cash and investments
- Approximately $28 million
- Balance as of Dec 31, 2025 year-end
- Current share price
- $10.23
- Price before this compliance announcement
- 52-week high distance
- -94.8%
- Price vs 52-week high of $196.7
- 52-week low distance
- 8.6%
- Price vs 52-week low of $9.42
- Relative volume
- 0.3x
- Today’s volume vs 20-day average
Historical Context
-
Announced 1-for-35 reverse split reducing outstanding shares to about 655k.
-
CEO scheduled for virtual investor segment and Q&A on Dec 3, 2025.
-
FDA upheld not-approvable letter for VenoValve; focus shifted to enVVe.
-
Reported Q3 2025 results with reduced net loss and cash runway commentary.
-
CEO discussed supervisory appeal to FDA after VenoValve not-approvable letter.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
minimum bid price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company achieves minimum
Reports Cash and Investments of approximately
IRVINE, CA / ACCESS Newswire / February 4, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of
The Company has made meaningful progress on its 2026 strategic plans and expects to share additional details in the coming weeks. The Company believes that regaining compliance with listing requirements, combined with a year-end cash and investments balance of approximately
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775
MEDIA CONTACT:
Glenn Silver, FINN Partners
Glenn.Silver@finnpartners.com
(973) 818-8198
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.